Design and characterization of inulin conjugate for improved intracellular and targeted delivery of pyrazinoic acid to monocytes

Simple item page
dc.contributor.authorAfinjuomo, F.
dc.contributor.authorBarclay, T.G.
dc.contributor.authorParikh, A.
dc.contributor.authorSong, Y.
dc.contributor.authorChung, R.
dc.contributor.authorWang, L.
dc.contributor.authorLiu, L.
dc.contributor.authorHayball, J.D.
dc.contributor.authorPetrovsky, N.
dc.contributor.authorGarg, S.
dc.date.issued2019
dc.descriptionData source: Supplementary material, https://doi.org/10.3390/pharmaceutics11050243
dc.description.abstractThe propensity of monocytes to migrate into sites of mycobacterium tuberculosis (TB) infection and then become infected themselves makes them potential targets for delivery of drugs intracellularly to the tubercle bacilli reservoir. Conventional TB drugs are less e ective because of poor intracellular delivery to this bacterial sanctuary. This study highlights the potential of using semicrystalline delta inulin particles that are readily internalised by monocytes for a monocyte-based drug delivery system. Pyrazinoic acid was successfully attached covalently to the delta inulin particles via a labile linker. The formation of new conjugate and amide bondwas confirmed using zeta potential, Proton Nuclear Magnetic Resonance (1HNMR) and Fourier transform infrared spectroscopy (FTIR). Scanning electron microscopy (SEM) confirmed that no significant change in size after conjugation which is an important parameter for monocyte targeting. Thermogravimetric analysis (TGA) and di erential scanning calorimetry (DSC) were used to establish the change in thermal properties. The analysis of in-vitro release demonstrated pH-triggered drug cleavage o the delta inulin particles that followed a first-order kinetic process. The e cient targeting ability of the conjugate for RAW 264.7 monocytic cells was supported by cellular uptake studies. Overall, our finding confirmed that semicrystalline delta inulin particles (MPI) can be modified covalently with drugs and such conjugates allow intracellular drug delivery and uptake into monocytes, making this system potentially useful for the treatment of TB.
dc.description.statementofresponsibilityFranklin Afinjuomo, Thomas G. Barclay, Ankit Parikh, Yunmei Song, Rosa Chung, Lixin Wang, Liang Liu, John D. Hayball, Nikolai Petrovsky and Sanjay Garg
dc.identifier.citationPharmaceutics, 2019; 11(5):243-1-243-22
dc.identifier.doi10.3390/pharmaceutics11050243
dc.identifier.issn1999-4923
dc.identifier.issn1999-4923
dc.identifier.orcidHayball, J.D. [0000-0002-3089-4506]
dc.identifier.urihttp://hdl.handle.net/2440/121038
dc.language.isoen
dc.publisherMDPI
dc.relation.granthttp://purl.org/au-research/grants/arc/LP140100142
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.source.urihttps://doi.org/10.3390/pharmaceutics11050243
dc.subjectInulin; pyrazinoic acid; intracellular delivery; tuberculosis
dc.titleDesign and characterization of inulin conjugate for improved intracellular and targeted delivery of pyrazinoic acid to monocytes
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_121038.pdf
Size:
3.75 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Medicine publications